Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Biogen_Inc.
|
| gptkbp:activities |
anti-inflammatory
neuroprotective |
| gptkbp:clinical_trial |
gptkb:relapsing_forms_of_multiple_sclerosis
NC T03416630 NC T03416643 NC T03416657 NC T03416674 NC T03416688 |
| gptkbp:contraindication |
pregnancy
breastfeeding severe liver impairment hypersensitivity to diroximel fumarate |
| gptkbp:dosage_form |
462 mg
|
| gptkbp:effective_date |
2020-10-29
|
| gptkbp:formulation |
gptkb:beer
|
| https://www.w3.org/2000/01/rdf-schema#label |
Vumerity
|
| gptkbp:ingredients |
gptkb:diroximel_fumarate
|
| gptkbp:invention |
2028-10-29
|
| gptkbp:is_used_for |
gptkb:psychologist
|
| gptkbp:label |
FDA approved labeling
|
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:Biogen
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:packaging |
gptkb:beer
|
| gptkbp:pharmacokinetics |
excreted in urine
improves quality of life metabolized in liver rapid absorption reduces relapse rate |
| gptkbp:population |
adults
|
| gptkbp:price |
approximately $60,000 per year
|
| gptkbp:provides_information_on |
included in MS treatment guidelines
|
| gptkbp:requires |
available online
|
| gptkbp:research |
ongoing studies on long-term effects
studies on efficacy in different populations investigating combination therapies studies on safety profile |
| gptkbp:scholarships |
available patient assistance programs
|
| gptkbp:side_effect |
fatigue
headache nausea abdominal pain diarrhea liver enzyme elevation increased risk of infections skin rash flushing |
| gptkbp:storage |
room temperature
|